Novartis TAPs ImmunoGen's antibody technology for anticancer targets
This article was originally published in Scrip
Executive Summary
Just a week after dropping the development of the Phase III antibody Mycograb (efungumab), Novartis is to pay $45 million upfront to use the US firm ImmunoGen's targeted antibody payload (TAP) technology to discover and develop targeted anticancer therapeutics.